



May 13, 2022

W. L. Gore & Associates, Inc.
Elizabeth Peterson
Aortic Regulatory Affairs
3450 West Kiltie Lane
Flagstaff, Arizona 86005

Re: P210032

Trade/Device Name: GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device)
Product Code: MIH
Filed: August 24, 2021
Amended: February 14, 2022

Dear Elizabeth Peterson:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) for the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device). This device is indicated for endovascular repair of lesions of the descending thoracic aorta, while maintaining flow into the left subclavian artery, in patients who are at high risk for debranching subclavian procedures and have:

- Adequate iliac/femoral access
- Proximal Aortic Landing Zones:
 - For Isolated Lesion Patients: Proximal landing zone cannot be aneurysmal, dissected, heavily calcified, or heavily thrombosed
 - For Dissection Patients: Primary entry tear must be distal to the left subclavian artery and the proximal extent of the landing zone must not be dissected
 - Aortic inner diameter range 16-42 mm
 - Proximal segment length (length from distal edge of left subclavian artery to mid left common carotid ostium) of at least 2.0-4.0 cm, depending on Aortic Component selection
 - Proximal covered length (measured from distal edge of left subclavian artery to distal edge of left common carotid artery ostium) of at least 15–36 mm, depending on Aortic Component selection
 - For patients with prior ascending aorta or aortic arch repair with a surgical graft: at least 2 cm landing zone proximal to the distal anastomosis
- Left Subclavian Landing Zone:
 - Landing zone cannot be aneurysmal, dissected, heavily thrombosed and severely tortuous (180 degree turn within the treated length)
 - Left subclavian artery inner diameter of 6–18 mm, depending on Side Branch Portal diameter selected
 - Left subclavian artery minimum length of 2.5–3.0 cm, depending on Side Branch Portal diameter selected
- Distal Landing Zone (Isolated Lesion Patients only)
 - Outer curve length must be ≥ 2 cm proximal to celiac artery

- Aortic inner diameter range 16-42 mm
- Non aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone
- Native Aorta or previously placed GORE® TAG® Conformable Thoracic Stent Graft

We are pleased to inform you that the PMA is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below. Although this letter refers to your product as a device, please be aware that some approved products may instead be combination products. The Premarket Approval Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm> identifies combination product submissions.

The sale and distribution of this device are restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). The device is further restricted under section 515(d)(1)(B)(ii) of the act insofar as the labeling must specify the specific training or experience practitioners need in order to use the device. FDA has determined that these restrictions on sale and distribution are necessary to provide reasonable assurance of the safety and effectiveness of the device. Your device is therefore a restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to the many other FDA requirements governing the manufacture, distribution, and marketing of devices.

Expiration dating for this device has been established and approved at 36 months. This is to advise you that the protocol you used to establish this expiration dating is considered an approved protocol for the purpose of extending the expiration dating as provided by 21 CFR 814.39(a)(7).

Continued approval of the PMA is contingent upon the submission of periodic reports, required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. This report, identified as "Annual Report" and bearing the applicable PMA reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.84.

In addition to the above, and in order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, the Annual Report must include, separately for each model number (if applicable), the number of devices sold and distributed during the reporting period, including those distributed to distributors. The distribution data will serve as a denominator and provide necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA evaluates the continued safety and effectiveness of the device.

You have agreed to provide a Clinical Update to physician users at least annually. At a minimum, this update will include, for the IDE and Post-Approval studies, respectively, a summary of the number of patients for whom data are available, with the rates of mortality (device- and lesion-related), stroke ($mRS \geq 2$), paraplegia / paraparesis, aortic enlargement in the region encompassed by the initial lesion, aortic rupture, Type I/III endoleaks, new dissections, loss of device integrity, device migration, loss of aortic / aortic branch patency, and additional surgical or interventional procedure related to the device or procedure. Reasons for secondary interventions and conversion to open surgery as well as causes of lesion-related death and rupture are to be described. Additional relevant information from commercial experience within and outside the United States

is also to be included. A summary of any explant analysis findings is to be included. The clinical update for physician users and the information supporting the updates must be provided in the Annual Report.

In addition to the Annual Report requirements, you must provide the following data in post-approval study (PAS) reports for each PAS listed below.

You must obtain approval of your PAS protocol(s) within 60 days from the date of this order. Within 30 days of your receipt of this letter, you must submit a PMA supplement that includes a complete protocol of your post-approval study described below. Your PMA supplement should be clearly labeled as a "PMA Post-Approval Study Protocol" as noted below and submitted to the address below. Please reference the PMA number above to facilitate processing. If there are multiple protocols being finalized after PMA approval, please submit each protocol as a separate PMA supplement.

1. *Continued Follow-up of the IDE Study Subjects*: This study is a non-randomized, multicenter, prospective study that consists of continued follow-up of all available subjects from the IDE Pivotal Study and the continued access subjects. The study design includes the assessment of the GORE® TAG® Thoracic Branch Endoprosthesis in treating lesions of the thoracic aorta in Zone 2. A total of 244 subjects were enrolled and eligible for analysis in the study across the 4 cohorts (including six continued access subjects). The remaining subjects will be followed annually for 5 years. Clinical outcomes include Procedural Success (defined as Device Technical Success with the absence of serious adverse events at 30 days, including: death, disabling stroke, paraplegia, paraparesis, new onset renal failure requiring permanent dialysis, unanticipated reintervention related to the device or the procedure, new ischemia, distal device-related thromboembolic events requiring intervention, life threatening bleed, myocardial infarction, prolonged intubation, laryngeal or phrenic nerve injury, renal dysfunction or volume overload requiring ultrafiltration, severe heart failure or hypotension, aortic rupture or new dissection) and Treatment Success (defined as Device Technical Success, with absence of all of the following at all appropriate follow-up windows: lesion-related mortality, disabling stroke, paraplegia and paraparesis, protocol-defined reintervention, new ischemia, aortic rupture, loss of patency, fistula formation, loss of device integrity, device migration, new dissection, Type I/III endoleak, and aortic enlargement). These endpoints will be analyzed descriptively, and PAS reports submitted on a yearly basis.
2. *GORE® TAG® Thoracic Branch Endoprosthesis Post-Market Surveillance Study*: This is a non-randomized, multicenter registry collecting data from consecutively treated patients. The objective of the registry is to ensure that the clinical outcomes during the commercial use of the GORE® TAG® Thoracic Branch Endoprosthesis are as anticipated. This study will enroll a minimum of 250 subjects and a maximum of 350 subjects treated with the GORE® TAG® Thoracic Branch Endoprosthesis with at least 100 subjects evaluable at 5 years post-implantation, and additional follow-up provided for all patients enrolled to 10 years unless lost to follow-up or subject death. This study will enroll a minimum of 45 Acute Type B Dissection subjects, 20 Other Isolated Lesions (including PAU and IMH) subjects, and 25 Traumatic Transection subjects. This study will have a minimum of 20 new sites and a maximum of 40 sites that were involved in the IDE. Subject follow-up for this registry is per standard medical practice at each participating site through 10 years post-treatment. Core Lab imaging analysis will be performed for the first five years and site reported imaging analysis through the ten years of the study. The analysis will include clinical data required to assess safety and performance of the GORE® TAG® Thoracic Branch Endoprosthesis, including:

patient and anatomical characteristics, procedural characteristics and outcomes, short-to-mid-term outcomes through 5 years, and long term outcomes from 5 years – 10 years (as available). The data collection will include: device- and lesion-related mortality, all-cause mortality, stroke (mRS ≥ 2), paraplegia / paraparesis, aortic enlargement ($>5\text{mm}$) in the region encompassed by the initial lesion, aortic rupture, Type I/III endoleaks, new dissections, loss of device integrity, device migration, loss of aortic / aortic branch patency, and additional surgical or interventional procedure related to the device or procedure. Outcomes will be reported using descriptive statistics.

From the time of study protocol approval, you must meet the following timelines for GORE® TAG® Thoracic Branch Endoprosthesis Post-Market Surveillance Study:

- First subject enrolled within 6 months
- 20% of subjects enrolled within 12 months
- 50% of subjects enrolled within 18 months
- 100% of subjects enrolled within 36 months
- Submission of Final study report: 3 months from study completion (i.e. last subject, last follow-up date)

In addition, you must submit separate periodic reports on the progress of GORE® TAG® Thoracic Branch Endoprosthesis Post-Market Surveillance Study as follows:

- PAS Progress Reports every six (6) months until subject enrollment has been completed, and annually thereafter.
- If any enrollment milestones are not met, you must begin submitting quarterly enrollment status reports (i.e., every 3 months), in addition to your periodic (6-months) PAS Progress Reports, until FDA notifies you otherwise.

For all other condition of approval studies, you must submit separate PAS Progress Reports for each study, every six (6) months for the first two (years) and annually thereafter, unless otherwise specified by FDA.

Each PAS report should be submitted to the address below identified as a "PMA Post-Approval Study Report" in accordance with how the study is identified above and bearing the applicable PMA reference number.

Be advised that failure to comply with any post-approval requirement, including complying with the PAS requirements outlined above, constitutes grounds for FDA withdrawal of approval of the PMA in accordance with 21 CFR 814.82(c) and 814.46(a)(2).

Be advised that the failure to conduct any such study in compliance with the good clinical laboratory practices in 21 CFR part 58 (if a non-clinical study subject to part 58) or the institutional review board regulations in 21 CFR part 56 and the informed consent regulations in 21 CFR part 50 (if a clinical study involving human subjects) may be grounds for FDA withdrawal of approval of the PMA in accordance with 21 CFR 814.46(a)(3)-(4).

Be advised that protocol information, interim and final results will be published on the Post Approval Study Webpage https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma_pas.cfm.

In addition, the results from any post approval study should be included in the labeling as these data become available. At a minimum, the labeling should be updated when all eligible subjects have completed 5-year and 10-year follow-up. Any updated labeling must be submitted to FDA in the form of a PMA Supplement. For more information on post-approval studies, see the FDA guidance document entitled, "Procedures for Handling Post-Approval Studies Imposed by PMA Order" (<https://www.fda.gov/media/71327/download>).

This is a reminder that as of September 24, 2014, class III devices are subject to certain provisions of the final Unique Device Identification (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, 21 CFR 814.84 (b)(4) requires PMA annual reports submitted after September 24, 2014, to identify each device identifier currently in use for the subject device, and the device identifiers for devices that have been discontinued since the previous periodic report. It is not necessary to identify any device identifier discontinued prior to December 23, 2013. Combination Products may also be subject to UDI requirements (see 21 CFR 801.30). For more information on these requirements, please see the UDI website, <https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-udi-system>.

Before making any change affecting the safety or effectiveness of the PMA device, you must submit a PMA supplement or an alternate submission (30-day notice) in accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-day notice) must comply with the applicable requirements in 21 CFR 814.39. For more information, please refer to the FDA guidance document entitled, "Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process" <https://www.fda.gov/media/81431/download>.

You are reminded that many FDA requirements govern the manufacture, distribution, and marketing of devices. For example, in accordance with the Medical Device Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52 for devices or post-marketing safety reporting (21 CFR 4, Subpart B) for combination products, you are required to report adverse events for this device. Manufacturers of medical devices, including in vitro diagnostic devices, are required to report to FDA no later than 30 calendar days after the day they receive or otherwise becomes aware of information, from any source, that reasonably suggests that one of their marketed devices:

1. May have caused or contributed to a death or serious injury; or
2. Has malfunctioned and such device or similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems> and on combination product post-marketing safety reporting is available at (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>).

In accordance with the recall requirements specified in 21 CFR 806.10 for devices or the post-marketing safety reporting requirements (21 CFR 4, Subpart B) for combination products, you are required to submit a written report to FDA of any correction or removal of this device initiated by you to: (1) reduce a risk to health posed by the device; or (2) remedy a violation of the act caused by the device which may present a risk to health, with certain exceptions specified in 21 CFR 806.10(a)(2). Additional information on recalls is available at

<https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/industry-guidance-recalls>.

CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. CDRH will notify the public of its decision to approve your PMA by making available, among other information, a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CDRH Internet Home Page located at

<https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/pma-approvals>. Written requests for this information can also be made to the Food and Drug Administration, Dockets Management Branch, (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by submitting a petition for review under section 515(g) of the act and requesting either a hearing or review by an independent advisory committee. FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of approval of a PMA. The introduction or delivery for introduction into interstate commerce of a device that is not in compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device, you must submit an amendment to this PMA submission with a copy of all final labeling. Final labeling that is identical to the labeling approved in draft form will not routinely be reviewed by FDA staff when accompanied by a cover letter stating that the final labeling is identical to the labeling approved in draft form. If the final labeling is not identical, any changes from the final draft labeling should be highlighted and explained in the amendment.

All required documents should be submitted, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing.

U.S. Food and Drug Administration
Center for Devices and Radiological Health
Document Control Center - WO66-G609
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

If you have any questions concerning this approval order, please contact Maiquyen Nguyen at 407-443-0307 or Maiquyen.Nguyen@fda.hhs.gov.

Sincerely,

Brian D. Pullin -S

for Nicole Ibrahim

Director

DHT2B: Division of Circulatory Support,
Structural and Vascular Devices

OHT2: Office of Cardiovascular Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health